TCGA-P3-A6T6-01A-11R-A34R-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.090182648
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.520
- E2F_TARGETS+0.460
- MYC_TARGETS_V1+0.410
- OXIDATIVE_PHOSPHORYLATION+0.400
- DNA_REPAIR+0.380
- SPERMATOGENESIS+0.280
- G2M_CHECKPOINT+0.240
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.110
- FATTY_ACID_METABOLISM+0.060
- ADIPOGENESIS+0.000
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.590
- TGF_BETA_SIGNALING-0.570
- INFLAMMATORY_RESPONSE-0.530
- APICAL_SURFACE-0.520
- IL6_JAK_STAT3_SIGNALING-0.520
- TNFA_SIGNALING_VIA_NFKB-0.520
- INTERFERON_ALPHA_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.480
- KRAS_SIGNALING_UP-0.470
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-AA75-01A-11R-A39I-07 | — | — | 0.949 |
| 2 | TCGA-TN-A7HI-01A-11R-A34R-07 | — | — | 0.936 |
| 3 | TCGA-CN-A63U-01A-11R-A30B-07 | — | — | 0.930 |
| 4 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.929 |
| 5 | TCGA-77-A5G7-01B-11R-A27Q-07 | — | cohortSQ1 | 0.924 |
| 6 | TCGA-CV-6948-01A-11R-1915-07 | — | — | 0.921 |
| 7 | SAMN03290897 | — | — | 0.918 |
| 8 | SRR8518240 | — | E | 0.917 |
| 9 | 4db3046e-1628-4cd7-a362-d169176d9fd8 | — | — | 0.914 |
| 10 | TCGA-OL-A5RZ-01A-11R-A28M-07 | — | C | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.410 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |